ZEB1 and endometrial cancer: Low dose metformin, at least in endometrial cancer cell lines, appears to reduce the expression of SNAI1, TWIST and ZEB1 and could, therefore, influence the metastatic process, although this has yet to be proven in primary endometrial cancer samples [46].